March 15 (Reuters) - The U.S. government said on Wednesday it will subject 27 drugs to inflation penalties, a move that will require the pharmaceutical companies to pay Medicare rebates if they raise prices at a faster pace than the rise in inflation rate. Under the new provisions, the government will start invoicing the companies for the rebates in 2025, but Medicare members will see a reduction in out-of-pocket costs starting April. Here is a list of the drugs and companies: DRUG NAME USED FOR MANUFACTURER U.S. NET SALES IN 2022 Humira Arthritis AbbVie Inc $18.62 billion Yescarta Blood cancer Gilead Sciences $747 Inc million Padcev Urothelial cancer Seagen Inc $451 million Xiaflex Peyronie's disease Endo $438.7 International million Plc Tecartus Blood cancer Gilead Sciences $221 Inc million Mircera Anemia Roche 408 million Swiss Francs ($442.66 million) in global sales Fetroja Serious bladder or Shionogi & Co 7.3 billion kidney infections Ltd yen in in adults Apr-Dec 2022 ($54.6 million) Fragmin Treat blood clots Pfizer Inc $4 million Abelcet Invasive fungal Leadiant Data infections Biosciences unavailable Akynzeo Prevention of Helsinn Data chemotherapy-induce Healthcare S.A unavailable d nausea and vomiting Atgam Used after kidney Pfizer Inc Data transplant to keep unavailable the body from rejecting the organ Aveed Treat low Endo Data testosterone in International unavailable adult males Plc Bicillin Antibiotic Pfizer Inc Data C-R unavailable Bicillin Antibiotic Pfizer Inc Data L-A unavailable Carnitor Carnitine Leadiant Data deficiency Biosciences unavailable Cytogam To prevent a Kamada Ltd Data cytomegalovirus unavailable disease infection in transplant patients Elzonris Rare form of blood Menarini Group Data cancer unavailable Flebogamma Treatment for Grifols SA Data DIF primary unavailable immunodeficiency and autoimmune disease Folotyn T-cell lymphoma Acrotech Data Biopharma LLC unavailable Leukine Blood cancer Partner Data Therapeutics unavailable Minocin To prevent Bausch Health Data infections in Companies unavailable hospitalized patients Nipent Blood cancer Pfizer Inc Data unavailable Rybrevant Lung cancer Johnson & Data Johnson unavailable Signifor For the rare Recordati Data LAR diseases Acromegaly unavailable and Cushing's disease Sylvant Multicentric EUSA Pharma (US) Data Castleman's disease LLC unavailable Winrho SDF Bleeding disorder Kamada Ltd's Data unavailable Xipere Eye disease macular Bausch and Data edema associated Lomb's unavailable with uveitis ($1 = 0.9217 Swiss francs) (Compiled by Aditya Samal and Leroy leo; Editing by Shinjini Ganguli)